Cell-based Assays Market Size, Share & Trends Analysis Report By Products & Services (Reagents, Assay Kits), By Application (Basic Research, Drug Discovery), By End-use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Cell-based Assays Market Growth & Trends
The global cell-based assays market size is expected treach USD 28.56 billion by 2030, registering a CAGR of 8.8% from 2025 t2030, according ta new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs tbe supplied robustly tcater tthe industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected tboost the demand. These assays are integral tthe drug development process by adopting several technologies, such as CRISPR-Cas9, tallow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.
For instance, Celprogen’s human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need tprepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies texpand their pipelines, portfolios, and offerings tpenetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services taid the acceleration of the development process of cancer therapeutics by reducing the time & cost tcharacterize solid tumors.
Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and tdevise new therapeutic regimes teffectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both tthe continuance of research activities and the type of assays performed.
There are efforts across the U.S. tensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay tstudy the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing tan increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected tregister the fastest CAGR from 2025 t2030 due tthe rising demand for research in life sciences and increased genetic level understanding of diseases.
Cell-based Assays Market Report Highlights
Cell-based Assays Market Growth & Trends
The global cell-based assays market size is expected treach USD 28.56 billion by 2030, registering a CAGR of 8.8% from 2025 t2030, according ta new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs tbe supplied robustly tcater tthe industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected tboost the demand. These assays are integral tthe drug development process by adopting several technologies, such as CRISPR-Cas9, tallow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.
For instance, Celprogen’s human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need tprepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies texpand their pipelines, portfolios, and offerings tpenetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services taid the acceleration of the development process of cancer therapeutics by reducing the time & cost tcharacterize solid tumors.
Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and tdevise new therapeutic regimes teffectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both tthe continuance of research activities and the type of assays performed.
There are efforts across the U.S. tensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay tstudy the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing tan increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected tregister the fastest CAGR from 2025 t2030 due tthe rising demand for research in life sciences and increased genetic level understanding of diseases.
Cell-based Assays Market Report Highlights
- The assay kits products segment accounted for the largest revenue share in 2024 due tthe utilitarian benefits that a test kit could offer tclinicians, researchers, and the normal population.
- Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days.
- The drug discovery application segment is expected tgrow at a lucrative CAGR over the forecast period.
- This is due ta rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases.
- The academic & research institutes end-use segment is expected tregister the fastest CAGR over the forecast period.
- The growth can be attributed tthe greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Products & Services
1.2.2. Application
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. CELL-BASED ASSAYS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence of Chronic Diseases
3.2.1.2. Growing Focus on Personalized Medicine
3.2.1.3. Technological Advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Complexity of Assay Development
3.2.2.2. Lack of Standardization
3.3. Cell-based Assays Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. CELL-BASED ASSAYS MARKET: PRODUCTS & SERVICES ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Cell-based Assays Market: Products & Services Movement Analysis
4.3. Cell-based Assays Market by Products & Services Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Reagents
4.5.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Assay Kits
4.6.1. Assay Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. Cell Growth Assays
4.6.2.1. Cell Growth Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. Reporter Gene Assays
4.6.3.1. Reporter Gene Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. Cell Death Assays
4.6.4.1. Cell Death Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Second Messenger Assays
4.6.5.1. Second Messenger Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Microplates
4.7.1. Microplates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Probes & Labels
4.8.1. Probes & Labels Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Instruments & Software
4.9.1. Instruments & Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10. Cell Lines
4.10.1. Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.2. Primary Cell Lines
4.10.2.1. Primary Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.3. Stem Cell Lines
4.10.3.1. Stem Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.4. Immortalized Cell Lines
4.10.4.1. Immortalized Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CELL-BASED ASSAYS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Cell-based Assays Market: Application Movement Analysis
5.3. Cell-based Assays Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Basic Research
5.5.1. Basic Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Drug Discovery
5.6.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Applications
5.7.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CELL-BASED ASSAYS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Cell-based Assays Market: End Use Movement Analysis
6.3. Cell-based Assays Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Pharmaceutical & Biotechnology Companies
6.5.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Contract Research Organizations
6.7.1. Contract Research Organizations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. CELL-BASED ASSAYS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. Bio-Rad Laboratories, Inc
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Corning Incorporated
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Merck KGaA
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Lonza Group AG
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Charles River Laboratories
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Becton, Dickinson and Company (BD)
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Danaher Corporation
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Promega Corporation
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Thermo Fisher Scientific Inc
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. F. Hoffmann-La Roche Ltd.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Products & Services
1.2.2. Application
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. CELL-BASED ASSAYS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence of Chronic Diseases
3.2.1.2. Growing Focus on Personalized Medicine
3.2.1.3. Technological Advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Complexity of Assay Development
3.2.2.2. Lack of Standardization
3.3. Cell-based Assays Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. CELL-BASED ASSAYS MARKET: PRODUCTS & SERVICES ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Cell-based Assays Market: Products & Services Movement Analysis
4.3. Cell-based Assays Market by Products & Services Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Reagents
4.5.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Assay Kits
4.6.1. Assay Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. Cell Growth Assays
4.6.2.1. Cell Growth Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. Reporter Gene Assays
4.6.3.1. Reporter Gene Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. Cell Death Assays
4.6.4.1. Cell Death Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Second Messenger Assays
4.6.5.1. Second Messenger Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Microplates
4.7.1. Microplates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Probes & Labels
4.8.1. Probes & Labels Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Instruments & Software
4.9.1. Instruments & Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10. Cell Lines
4.10.1. Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.2. Primary Cell Lines
4.10.2.1. Primary Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.3. Stem Cell Lines
4.10.3.1. Stem Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10.4. Immortalized Cell Lines
4.10.4.1. Immortalized Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CELL-BASED ASSAYS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Cell-based Assays Market: Application Movement Analysis
5.3. Cell-based Assays Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Basic Research
5.5.1. Basic Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Drug Discovery
5.6.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Applications
5.7.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CELL-BASED ASSAYS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Cell-based Assays Market: End Use Movement Analysis
6.3. Cell-based Assays Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Pharmaceutical & Biotechnology Companies
6.5.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Contract Research Organizations
6.7.1. Contract Research Organizations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. CELL-BASED ASSAYS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. Bio-Rad Laboratories, Inc
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Corning Incorporated
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Merck KGaA
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Lonza Group AG
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Charles River Laboratories
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Becton, Dickinson and Company (BD)
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Danaher Corporation
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Promega Corporation
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Thermo Fisher Scientific Inc
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. F. Hoffmann-La Roche Ltd.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
